From July 1, 2022 to September 24, 2022, the company has repurchased 14,499,918 shares, representing 0.73% for CNY 131.9 million. With this, the company has completed the repurchase of 15,699,918 shares, representing 0.78% for CNY 143.57 million under the buyback announced on June 15, 2022.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.33 CNY | -1.58% | -6.61% | -13.85% |
May. 15 | Tonghua Dongbao Pharmaceutical Launches Phase 1 Trial for Diabetes Injection in China | MT |
May. 10 | Dongbao Pharmaceutical's Deputy General Manager to Reduce Stake | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-13.85% | 2.54B | |
-2.95% | 90.75B | |
-1.97% | 39.03B | |
-15.47% | 31.85B | |
+62.10% | 26.26B | |
-22.81% | 14.13B | |
-8.82% | 12.87B | |
-11.77% | 11.6B | |
-45.97% | 10.91B | |
+3.30% | 8.89B |
- Stock Market
- Equities
- 600867 Stock
- News Tonghua Dongbao Pharmaceutical Co., Ltd.
- Tranche Update on Tonghua Dongbao Pharmaceutical Co., Ltd.'s Equity Buyback Plan announced on June 15, 2022.